STOCK TITAN

Velan Capital lifts Edesa Biotech (EDSA) stake to 9.99% with warrant leverage

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Edesa Biotech, Inc. (EDSA) is the subject of an amended Schedule 13D/A filed by Velan Capital–affiliated entities following an underwritten public offering on August 21, 2026. The Velan Master, Horizon and Opportunity II funds acquired additional common shares and warrants in the transaction.

Velan Master purchased 445,100 Shares and 445,100 New Warrants for $2,448,050, and Velan Horizon purchased 9,445 Shares and 9,445 New Warrants for $51,948. Overall, Velan Capital and related reporting persons may be deemed to beneficially own 1,356,455 Shares, or 9.99% of the class, based on 13,503,723 Shares outstanding plus certain convertible Preferred Shares, subject to ownership caps. The New Warrants are exercisable into an equal number of Shares at $7.50 per Share, until the earlier of 18 months from issuance or 30 days after Edesa publicly announces Phase 2 vitiligo topline data for EB06, and are subject to a 9.99% Warrant Ownership Limitation. Without the Ownership Limitation and Warrant Ownership Limitation, the group states it would collectively beneficially own 4,694,923 Shares, or 27.8% of the outstanding Shares.

Positive

  • None.

Negative

  • None.
Beneficial ownership (group) 1,356,455 Shares (9.99%) Aggregate beneficial ownership by Velan Master, Velan Horizon and Velan Opportunity II and related reporting persons
Shares outstanding 13,503,723 Shares Shares believed outstanding as of August 21, 2026 following the offering
Velan Master holdings 1,081,385 Shares (8.0%) Includes 74,410 Shares underlying certain Preferred Shares
Velan Opportunity II holdings 250,000 Shares (1.9%) Directly beneficially owned by Velan Capital Opportunity Fund II LLC
Velan Horizon holdings 25,070 Shares (0.2%) Directly beneficially owned by Velan Horizon Fund
Offering purchases (Velan Master) $2,448,050 for 445,100 Shares and 445,100 New Warrants Acquired in the August 21, 2026 underwritten public offering
Offering purchases (Velan Horizon) $51,948 for 9,445 Shares and 9,445 New Warrants Acquired in the August 21, 2026 underwritten public offering
New Warrant exercise price and potential ownership $7.50 per Share; 4,694,923 Shares (27.8%) without caps Exercise price per Share and potential aggregate beneficial ownership absent Ownership Limitations
Preferred Shares financial
"including 74,410 Shares underlying certain Preferred Shares"
Preferred shares are a type of investment that gives investors priority over common shareholders when it comes to receiving dividends and getting their money back if a company is sold or liquidated. Think of them as a safer, more predictable way to earn income from a company's profits, similar to a fixed-return investment, but without voting rights. This makes preferred shares appealing to those seeking stable income with a higher claim on assets than regular stockholders.
New Warrants financial
"purchased 445,100 Shares and 445,100 New Warrants for $2,448,050"
Ownership Limitation regulatory
"subject to the Ownership Limitation (as defined in the initial )"
Warrant Ownership Limitation regulatory
"not to any percentage in excess of 9.99% (the "Warrant Ownership Limitation")"
underwritten public offering financial
"On August 21, 2026, in an underwritten public offering (the "Offering")"
An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.
beneficially own regulatory
"may be deemed to beneficially own the 1,356,455 Shares beneficially owned"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.

FAQ

How much of Edesa Biotech (EDSA) do the Velan Capital reporting persons currently beneficially own?

They may be deemed to beneficially own 1,356,455 Shares of Edesa Biotech, representing approximately 9.99% of the outstanding Shares, based on 13,503,723 Shares outstanding plus Shares underlying certain Preferred Shares, subject to an Ownership Limitation.

What did Velan Master purchase in Edesa Biotech (EDSA) on August 21, 2026?

Velan Master purchased 445,100 Shares and 445,100 New Warrants of Edesa Biotech in an underwritten public offering for an aggregate purchase price of $2,448,050.

What did Velan Horizon buy in the Edesa Biotech (EDSA) offering?

Velan Horizon purchased 9,445 Shares and 9,445 New Warrants of Edesa Biotech for an aggregate purchase price of $51,948 in the same August 21, 2026 offering.

What is the exercise price and term of the New Warrants on Edesa Biotech (EDSA) shares?

Each New Warrant is exercisable for one Edesa Biotech Share at an exercise price of $7.50 per Share, exercisable any time after issuance until the earlier of the 18-month anniversary of issuance or 30 days after Edesa announces Phase 2 vitiligo topline data for EB06.

What ownership limitations apply to Velan’s New Warrants in Edesa Biotech (EDSA)?

Velan Master and Velan Horizon may not exercise New Warrants to the extent they would beneficially own more than 9.99% of Edesa’s Shares after exercise, under a Warrant Ownership Limitation that can be adjusted with at least 61 days’ notice but not above 9.99%.

What percentage of Edesa Biotech (EDSA) could the Velan group own without ownership caps?

Without the Ownership Limitation and Warrant Ownership Limitation, the reporting persons state they would collectively beneficially own 4,694,923 Shares of Edesa Biotech, representing approximately 27.8% of the outstanding Shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





27966L306

(CUSIP Number)
Adam Morgan
Velan Capital Investment Management LP, 100 North Main Street, Suite 301
Alpharetta, GA, 30009
646-844-0030


Ryan Nebel
Olshan Frome Wolosky LLP, 1325 Avenue of the Americas
New York, NY, 10019
212-451-2300

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
08/21/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Velan Capital Master Fund LP
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan, Managing Member of Velan Capital Holdings LLC, its General Partner
Date:08/25/2026
Velan Horizon Fund LP
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan, Managing Member of Velan Horizon GP LLC, its General Partner
Date:08/25/2026
Velan Capital Opportunity Fund II LLC
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan, Managing Member of Velan Capital Holdings LLC, its Managing Member
Date:08/25/2026
Velan Horizon GP LLC
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan, Managing Member
Date:08/25/2026
Velan Capital Holdings LLC
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan, Managing Member
Date:08/25/2026
Velan Capital Investment Management LP
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan, Managing Member of Velan Capital Management LLC, its General Partner
Date:08/25/2026
Velan Capital Management LLC
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan, Managing Member
Date:08/25/2026
Morgan Adam
Signature:/s/ Adam Morgan
Name/Title:Adam Morgan
Date:08/25/2026
VENKATARAMAN BALAJI
Signature:/s/ Balaji Venkataraman
Name/Title:Balaji Venkataraman
Date:08/25/2026